PROTAC technology represents a major shift in modern drug design, moving beyond protein inhibition toward directly eliminating disease-causing proteins. Unlike traditional drugs that must block a specific active site, PROTACs work by guiding unwanted proteins to the cell’s natural disposal system. Once the protein is tagged and destroyed, the PROTAC molecule is released and can repeat the process, making it highly efficient.
A key strength of PROTACs is their ability to act on proteins that were previously considered “undruggable.” Because they remove the entire protein rather than just suppressing its activity, they can work at lower doses and may overcome resistance caused by genetic mutations. This approach has advanced quickly, with multiple PROTAC drugs now in clinical trials and encouraging results seen in breast cancer, prostate cancer, and blood cancers.
However, PROTACs also face challenges due to their large and complex molecular structure, which can limit absorption, reduce stability, and increase the risk of side effects in healthy tissues. To overcome these issues, researchers are turning to nanotechnology-based delivery systems. Encapsulating PROTACs in nanoparticles may improve targeting, protect the drug in the bloodstream, and reduce toxicity, helping bring this promising strategy closer to everyday cancer treatment.